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1.1. Bacillus of Calmette and Guerin (BCG)
Mycobacterium bovis (M. bovis) is a bacterium that causes tuberculo-
sis in cattle and may also infect and cause illness among other animals,
including humans. In humans,M. bovis affects lungs, lymph nodes, and
other parts of the body. The original M. bovis Bacillus Calmette Guérin
vaccine strain has developed into several different sub-strains which
have been used for the production of BCG vaccines since 1921, and is
used to immunize against tuberculosis since 1948 [1,2,3]. Beginning in
the 1950s, cancer immunologist Lloyd J. Old and other researchers at
Sloan Kettering began investigating BCG as a treatment for cancer [4],
and subsequent clinical studies demonstrated the effectiveness of this
therapy for early-stage bladder cancer [5,6]. BCG has been used for
treatment of non-muscle invasive bladder cancer since the early
1990's. The product referred as BCG Immunotherapeutic (BCG IT), or
ImmuCyst® is a live attenuated bacterium; thus particles are inherent
part of this product and may be important for immunogenicity. It is
therefore informative to assess particle size as a potential quality attri-
bute. In thiswork for theﬁrst timewe present characterization of visible
and subvisible particles in the BCG IT product, ImmuCyst®.(M. Kirkitadze).
B.V. on behalf of the ResearchNetwor
.1.2. Purpose and scope of the study
Reconstituted lyophilized BCG IT product represents a heteroge-
neous suspension of particles with sizes in the visible and the sub-
visible ranges. A suitable method was required for particle size and dis-
tribution of reconstituted lyophilized BCG IT suspension, in order to gain
knowledge about (a) the product and (b) the performance of the
manufacturing process.
Previously, a Laser Diffraction method was used to characterize size
distribution of BCG IT products, while an Electrical Sensing Zone (ESZ)
method was used for particle count, i.e. number of particles per mL.
The design of the Coulter CounterMultisizer 4® instrument allows sam-
ple measurement in a conﬁned chamber that prevents potential spread
of aerosols in the laboratory. Since BCG IT is a live attenuated bacterium,
this design was preferred over that of theMastersizer 3000 instrument,
in which the wet dispenser is not able to prevent aerosol release during
the sample introduction step. Accordingly, an ESZ method was devel-
oped to measure both the particle count and the size distribution of
BCG IT product, using a Multisizer 4 instrument.
Three production scale BCG IT lots were used for ESZ method devel-
opment and optimization experiments, including a study to assess
method precision. In order to support future process consistency and
comparability studies, 20 additional production scale lots representa-
tive of the manufacturing process were used to establish a baseline set
of ESZ data. Such data sets can provide information about the perfor-
mance of the manufacturing process, as well as support future lot com-
parability studies [7]. In addition, it is useful to assess particle size and
distribution as a potential product quality attribute. Unlike most smallk of Computational and Structural Biotechnology. This is an open access article under the CC
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and sub-visible particles as endogenous components. Furthermore, the
particulate nature of vaccines and other immunogenic formulations is
well known to impact the host immune response. Thus, particle size
and distribution is an interesting parameter to investigate from the per-
spective of lot consistency and product knowledge. In this study, the
particle size and concentration measured by ESZ method for the lots
of BCG IT product ImmuCyst® is described for the ﬁrst time.
The scope of this studywas limited to the Connaught strain only, as it
is used to manufacture BCG IT product, ImmuCyst®. Other strains may
produce particles of different size compared to Connaught. While it
would be interesting to look at the particle size distribution of other
BCG strains, such studies would require equivalent processing of the
strain as per our current manufacturing process.1.3. Analysis of particle dispersion using ESZ
ESZ is a method to determine the number and size of particles
suspended in an electrolyte by causing them to pass through a small or-
iﬁce in an electric ﬁeld. Particles suspended in a weak electrolyte solu-
tion are drawn to a small aperture separating two electrodes through
which an electric current ﬂows. The voltage applied across the aperture
creates a “sensing zone”. As each particle passes through the aperture it
displaces is own volume of conducting liquid, momentarily increasing
the impedance of the aperture. The changes in electrical impedance as
particles pass through the oriﬁce generate voltage pulses whose ampli-
tudes are proportional to the volumes of the particles. The pulses are
ampliﬁed, sized and counted and from the derived data the size distri-
bution and particle concentration of the suspended phase can be deter-
mined. The method allows to determine size and concentration for
particles from submicron to visible size (~400 nm to 1600 μm) depend-
ing on the system, andmultiple apertures are required to cover this size
range.
The method was originally applied to blood cell counting [8–10].
Kubitschek [11,12,13] introduced modiﬁcations which permitted
counting of bacterial cells, and pointed out that this principle could be
applied to the measurement of cell-volume distributions as well as
number counting. Modiﬁed instruments were soon developed with
which particles could be sized as well as counted, e.g. Multisizer 4
(Beckman Coulter).
An advantage of ESZ is that it does not depend on optical properties
of particles and formulations. As such, it is a useful complementaryFig 1. Concentration of sub-visible particles according to their size in BCG\\IT sample. Sub-visib
measured by the 280 μm aperture. As the graph illustrates, smaller particles are more prominetechnique to light based particle sizing techniques (e.g. laser diffraction,
light obscuration, and ﬂow imaging microscopy).
2. Materials and methods
2.1. BCG IT sample preparation
The BCG IT product is based on the Connaught sub-strain, which
originated from the BCG parent strain of the Pasteur Institute in the
late 1920s [3]. All three BCG IT lots were manufactured by Sanoﬁ Pas-
teur, Toronto, Ontario, Canada and were lyophilized and sealed in
glass vials. Typically, saline is used as diluent for BCG IT prior to patient
administration. In this study, ISOTON® II electrolyte solution (Beckman
Coulter) which contains 0.9MNaCl inwater was used as a diluent. Each
BCG IT lot was dissolved in 3mL of ISOTON® II and stirred continuously
using a small magnet placed inside each vial on a stirring plate.
Particle counts and size distributions were measured by ESZ using a
Coulter Counter Multisizer 4 instrument (Beckman Coulter, Brea, CA,
USA). The particle size distribution of the reconstituted lyophilized
BCG IT product was reported using derived diameters: d10, d50, and
d90, whereas the concentration of the sub-visible particles was
expressed as number of particles per mL. The dispersion of BCG IT sus-
pension for 20 representative lots was expressed by the span, which is
deﬁned as (d90–d10)/d50, and is indicative of the polydispersity of
the sample [14].
2.2. ESZ procedure
ESZ was performed using Beckman Coulter Multisizer 4® instru-
ment (Beckman Coulter, Brea, CA, USA) equipped with the Multisizer4
software. A 280 μm aperture and a 1000 μm aperture were calibrated
using 90 μm standard latex beads (Beckman Coulter). Each aperture is
calibrated during vendor installation. The calibration records are
retained by the software and can be retrieved for subsequent uses. For
the particle count and size distribution measurements, a clean ST
Beaker® (Beckman Coulter) was ﬁlled with 400mL ISOTON® II electro-
lyte solution. Sample preparation and handling was performed asepti-
cally in a laminar ﬂow biocontainment cabinet. A 1.0 mL aliquot of
stirred BCG IT sample was added to the solution in the 400 mL ST
Beaker® and stirred in the Multisizer 4® during the entire experiment.
For the size distribution measurement only to detect larger particles
with the 1000 μm aperture, a clean ST Beaker® was ﬁlled with 400 mL
of ISOTON® II electrolyte solution and glycerol 6:4 mixture. A 1 mLle particle concentrations, reported as number per mL, according to their size, in μm, were
nt in reconstituted BCG IT samples.
Fig 2. Size distribution of particles in BCG IT samplemeasured by the 280 μmaperture. Visible and sub-visible particle size distribution in reconstitutedBCG ITproductwasmeasuredby the
280 μm aperture and reported as percentage of volume analyzed through the aperture. By % volume, the size distribution has a bell-curve distribution that peaks around 26 μm.
156 M. Kirkitadze et al. / Computational and Structural Biotechnology Journal 14 (2016) 154–160aliquot of stirred BCG IT sample was added to the 400 mL ST Beaker®
and stirred in the Multisizer 4® during the entire experiment.
As discussed above, the analysis was done using two apertures,
280 μm and 1000 μm to allow full coverage of the particle size distribu-
tion. In general, the events of aperture blockage, low current, air in the
aperture, the analyst is alerted, and the experiment is discontinued. In
addition, in the event of blockage the particle concentration detected
would be much lower than reported. In case of the 280 μm and
1000 μmapertures, no blockagewas observed during the run. However,
in case of 1000 μm aperture that consumes most of the sample during
the run, a 90 s acquisition time was set to avoid air getting into the
system.2.3. Reportable values
The particle size distribution of the reconstituted lyophilized BCG IT
product was reported using derived diameters: d10, d50, and d90,Fig. 3. Size distribution of particles in BCG IT samplemeasuredwith the 1000 μmaperture. Visibl
1000 μm aperture and reported as percentage of volume analyzed through the aperture. By %whereas the concentration of the sub-visible particles was expressed
as number of particles per mL. The dispersion of BCG IT suspension for
20 representative lots was expressed by the span, which is deﬁned
as (d90–d10)/d50, and is indicative of the polydispersity of the
sample [14].3. Results and discussion
3.1. Development and optimization of the ESZ method
The purpose of ESZ method development and optimization was to
demonstrate that this method is appropriate to measure the size distri-
bution of visible and sub-visible particles, and count of sub-visible par-
ticles in BCG IT samples. The scope of ESZ method development and
optimization included the choice of sample lots, sample preparation, in-
strument parameters, and an assessment of precision. The precision of
the ESZ method was evaluated through a lot-to-lot and analyst-to-e and sub-visible particle size distribution in reconstituted BCG IT productmeasured by the
volume, the size distribution is a left-skewed bell-curve that peaks around 56 μm.
Table 1
Particle concentration and derived diameters for three BCG IT lots using the 280 μm
aperture.
Trial lot (T) Mean, μm Concentration,
number per mL
d10, μm d50, μm d90, μm
T1 1st run 11.5 10.7 × 107 11.4 23.0 42.9
T1 2nd run 11.5 11.5 × 107 11.3 22.9 42.8
T2 2 1st run 11.9 11.0 × 107 12.5 26.8 50.4
T2 2 2nd run 11.9 11.0 × 107 12.5 26.6 49.8
T3 3 1st run 12.2 10.9 × 107 13.0 27.7 52.5
T3 3 2nd run 12.2 10.8 × 107 13.0 27.8 53.0
Average 11.87 11.0 × 107 12.28 25.80 48.57
Std. Dev. 0.31 0.28 × 107 0.76 2.26 4.59
%CV 2.6 2.5 6.2 8.7 9.4
The average, standard deviation, coefﬁcient of variation were shown in bold.
Table 2
Derived diameters of three lots BCG lots using the 1000 μm aperture.
Lot d10, μm d50, μm d90, μm
T1 1st run 29.7 50.5 114.0
T1 2nd run 29.6 48.9 81.6
T2 2 1st run 35.3 64.6 136.4
T2 2 2nd run 35.4 62.7 119.6
T3 3 1st run 32.2 52.2 82.2
T3 3 2nd run 32.6 55.1 89.8
Average 32.5 55.7 103.9
Std. Dev. 2.55 6.54 22.68
%CV 7.9 11.7 21.8
The average of derived diameters were shown in bold.
Table 4
ESZ qualiﬁcation study — statistical analysis of results for one lot of BCG IT.
Variable Repeatability (%CV) Intermediate precision (%CV)
Run 1 Run 2 Run 3 Overall
d10 2.65% 0.25% 1.20% 1.36% 1.73%
d50 2.18% 0.15% 0.67% 1.00% 1.69%
d90 2.36% 0.65% 1.58% 1.53% 2.05%
Span 1.98% 1.04% 1.63% 1.55% 1.43%
Concentration 0.45% 0.05% 0.05% 0.19% 0.31%
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tion, data collection and analysis procedures. The derived diameters,
d10, d50, and d90, and particle concentrations from the different runs
were collected and analyzed statistically to assess precision.
Normally one representative product lot is sufﬁcient for a method
development study. However, in this case three in-house non-
commercial lots representative of BCG IT lyophilized ﬁlled product
were used to develop the sample preparation procedures andMultisizer
4 instrumental parameters suitable to measure particle concentration
and size distribution.
Under the assumption that a sub-population of BCG IT particles fell
within the visible range, an aperture of 1000 μmwas initially selected
to detect the larger particles. An aperture of 280 μmwas used to mea-
sure particle concentration and size distribution in the range 5–
168 μm. The measurements of particle concentration and size distribu-
tion were performed by two analysts for the three reconstituted BCG
IT lots as described above under the heading “ESZ Procedure”. All BCG
IT samples were reconstituted and stirred directly in the sample vial
to ensure a uniform suspension of the particles. An aliquot of a continu-
ously stirred BCG IT sample was then taken and diluted 1:400 in the
electrolyte solution for the ESZ analysis. The length of experiment,
90 s, was determined as the time at which the level of the analyte isTable 3
ESZ qualiﬁcation study — summary of results for one lot of BCG IT.
d10 (μm) d50 (μm)
Day 1, analyst 1 Run 1 13.33 27.68
Run 2 13.14 26.92
Run 3 12.66 26.52
Day 2, analyst 2 Run 1 12.99 27.02
Run 2 12.94 26.96
Run 3 13.00 26.94
Day 3, analyst 1 Run 1 13.43 27.86
Run 2 13.15 27.49
Run 3 13.16 27.70
Average 13.09 27.23
The average of derived diameters, span, and concentration were shown in bold.just above the oriﬁce of the aperture; this corresponded to approxi-
mately 300 mL of analyte solution aspirated by either the 280 μm or
1000 μm aperture. The precision for measuring particle count and size
distribution of BCG IT vaccine was assessed by evaluating lot-to-lot
and analyst-to-analyst variability.
Examples of particle concentration and size distribution proﬁles are
shown in Figs. 1–3. The results obtained for three representative lots of
BCG IT are summarized in Tables 1–2.
The observed particle count and size distribution proﬁles were con-
sistent for the three lots of BCG IT product (Tables 1–2). The %CV value
obtained for the particle concentration expressed as number per mL
was 2.5%. The values of calculated %CV for precision of derived diameter
measurements using the aperture of size 280 μm were 6.2%, 8.7%, and
9.4% for d10, d50, and d90 respectively. The %CV values for derived di-
ameters measured by the aperture of size 1000 μm were higher, 7.9%,
11.7%, and 21.8% for d10, d50, and d90 respectively.
Accordingly, the ESZ method was judged to be appropriate for mea-
suring particle count and concentration of BCG IT using the 280 μm ap-
erture, based on the overall lower %CV values obtained with two runs
over the three lots. In addition, as shown in Fig. 3, a population of the
particles below 25 μm in diameter was not detected using the aperture
of size 1000 μm. In contrast, the aperture of size 280 μm detects the en-
tire population of the BCG IT particles in the range of 5–168 μm (Fig. 2).
Independent experiment (results not shown) using Mastersizer
2000 demonstrated that three lots BCG IT lots showed the Dv50 in the
range of 19.9–45.7 μm. The variability was greater from run to run for
the same lot. The samples were reconstituted in 0.9% saline, and dis-
pensed inMilli Q water, andmeasured at themixing speed of 2205 rpm.
Moreover, use of the 280 μmaperture for both the particle count and
size distribution measurements reduces both the overall experimental
time, and the amount of BCG IT sample required for the measurement.
Based on the results of this study, it was thus decided to use the
280 μm aperture for the baseline assessments of the multiple produc-
tion scale BCG IT lots.
3.2. Qualiﬁcation of ESZ method
Assay qualiﬁcation was performed to demonstrate that the method
is scientiﬁcally sound and suitable for its intended use. The qualiﬁcation
study consisted of a method precision assessment. The precisiond90 (μm) Span Concentration (# per mL)
53.02 1.434 1.087 × 108
50.73 1.396 1.095 × 108
51.16 1.452 1.096 × 108
51.10 1.410 1.090 × 108
51.61 1.434 1.090 × 108
51.73 1.438 1.089 × 108
53.37 1.434 1.088 × 108
52.11 1.417 1.087 × 108
53.70 1.464 1.087 × 108
52.06 1.431 1.090 × 108
Fig. 4. Sub-visible particles concentration in the 20 lots of BCG IT Concentration of sub-visible particleswasmeasured on20 production-scale lots of BCG IT to build an empirical baseline for
the manufacturing process.
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cine was assessed by evaluating day-to-day and analyst-to-analyst var-
iability. The qualiﬁcation study was performed using one lot, and
included three repeats of particle concentration (i.e. number per mL)
determination, and size distribution parameters d0, d50, d90 collected
during by two analysts over three days. The span was used to describe
distribution width. In total, there were nine measurements in total for
both particle concentration and size distribution (Table 3).
Repeatability was assessed using three reportable values generat-
ed by the same analyst within the same day. The Coefﬁcient of
Variation (CV) in % was calculated for the three reportable values
as per Eq. (1): %CV = (standard deviation ÷ mean) × 100%. Repeat-
ability was assessed for each analyst-day combination; therefore,
there are three %CV values reported per reportable value. Intermedi-
ate precision was assessed by having two analyst performing a total
of 9 independent measurements for 3 days (9 reportable values)
using the samples of the same lot of BCG IT. The %CV was calculated
based on the 9 measurements (Table 4).
The intermediate precision and repeatability %CVwere below 3% for
all reportable values (Table 4). There is no pre-deﬁned desirable meth-
od performance for this qualiﬁcation study, the low%CVvalues obtained
were judged to be acceptable. Qualiﬁcation of the ESZprocedure for BCGFig. 5. Particle size distribution in the 20 lots of BCG IT Particle size distribution proﬁles were coll
the manufacturing process.IT demonstrated that the method is suitable for its intended purpose,
and will be used to support comparability studies of the BCG IT product
[15,16].
3.3. Creating a baseline for the manufacturing process
Twenty lots of BCG IT were manufactured in order to conﬁrm that
the process at full scale can be run according to the established product
speciﬁcations, up to the lyophilized product stage. These lots were per-
formed at full scale in the existing manufacturing facility.
Process consistency for these lots was assessed from the standpoint
of particle concentration and size distribution in BCG IT reconstituted ly-
ophilized suspension. To address these parameters, ESZ reportable
values were collected using the 280 μm aperture for the 20 BCG IT lots
(Figs. 4, 5, Table 5).
The derived diameters and particle concentrations for the 20 lots of
BCG IT are summarized in Table 5, andwere consistent across the 20 lots
analyzed. For particle concentration, derived diameters d10 and d50,
the coefﬁcients of variation for all measurements were below 10%,
whereas for d90, %CV was slightly higher, at 13.8%. While the %CV
from these 20 BCG IT lots are slightly higher for d90 and particle concen-
tration compared to the ones collected from the three non-commercialected for 20 production-scale lots of BCG IT to build an empirical baseline for consistency of
Table 5
Particle concentration and derived diameters for 20 BCG lots using the 280 μm aperture.
Lot Concentration,
number per mL
d10, μm d50, μm d90, μm Span
(d90-d10)/d50
1SP 10.7 × 107 14.5 34.6 76.2 1.78
2SP 10.7 × 107 14.6 34.4 72.7 1.69
3SP 12.7 × 107 14.0 32.3 64.4 1.56
4SP 11.2 × 107 13.1 28.4 54.6 1.46
5SP 11.2 × 107 12.8 27.0 52.2 1.46
6SP 10.8 × 107 14.5 32.4 64.4 1.54
7SP 12.4 × 107 14.6 33.5 70.1 1.66
8SP 10.4 × 107 13.9 29.9 56.8 1.43
9SP 10.6 × 107 14.1 30.0 59.5 1.51
10SP 10.7 × 107 13.8 29.0 56.7 1.48
11SP 10.9 × 107 13.6 28.1 53.5 1.42
12SP 10.6 × 107 14.1 30.4 63.1 1.61
13SP 10.1 × 107 13.8 29.9 59.8 1.54
14SP 10.9 × 107 13.5 27.8 51.5 1.37
15SP 10.4 × 107 14.7 33.4 78.5 1.91
16SP 10.6 × 107 14.0 29.6 56.7 1.44
17SP 10.5 × 107 14.6 31.4 60.9 1.47
18SP 10.6 × 107 14.2 29.9 56.0 1.40
19SP 10.5 × 107 14.5 31.4 62.6 1.53
20SP 10.4 × 107 14.7 32.0 62.0 1.48
Average 10.8 × 107 14.0 30.6 61.9 1.54
Std. Dev. 0.66 × 107 0.55 2.49 8.55 0.14
%CV 6.14 3.91 8.16 13.81 8.81
The average of concentration, derived diameters, and span were shown in bold.
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between representative manufactured lots.
The dispersion of BCG IT suspension, as expressed by the span
(Table 5), was 1.54 on average, with %CV of 8.8. This shows that the
overall dispersion for BCG IT suspension was consistent for the 20
representative lots.
Overall, these results conﬁrm that ESZ is an appropriate method for
measuring particle concentration and size for BCG IT vaccine.
4. Conclusions
The analysis of the particle count and size distribution results for
BCG IT during method development, optimization, and qualiﬁcation
showed that the ESZ method was appropriate for measuring particle
concentration and size distribution. Therefore, thismethodwas selected
to assess the consistency of the manufacturing process over 20 produc-
tion scale lots of BCG IT.
ESZ can be used tomeasure both particle count and size distribution
of BCG IT using the aperture of size 280 μm in the same instrument, re-
ducing overall experimental time and sample volume requirements.
The use of a single method (ESZ) for measurement of both particle
count and size distribution simpliﬁes the characterization package as
this was previously done using two methods, Laser Diffraction for size
distribution and ESZ for particle count.
In addition, the design of Coulter Counter Multisizer 4® requires a
lower amount of the diluent (electrolyte) compared to a typical Laser
Diffraction instrument (e.g. Mastersizer series 2000 and 3000), and
fewer cleaning steps required due to the use of electrolyte solution
(ISOTON II®) that prevents adsorption of samples to the aperture and
other parts of the instrument.
Qualiﬁcation of the ESZ procedure for BCG IT demonstrated that the
method is suitable for its intended purpose, and will be used to support
comparability studies of the BCG IT product [15,16].
For any biological product, a characterization package consisting of
relevant analytical methods will expedite product development
through gaining of product knowledge, assessing lot-to-lot consistency
and the impact of process change and identifying potential product
quality attributes [17]. ESZ is an instrument-based method that does
not need any alterations to the sample, which is especially important
at the ﬁnal product stage of manufacturing. In addition, ESZ can beperformed on complex formulations, such as adjuvanted vaccines as
well as products with visible and/or sub-visible particles as endogenous
components. As a part of a test package for investigational products, ESZ
offers considerable advantages as a method for particle count and size
distribution assessment.
Considering the importance of BCG IT for clinical use such as
intravesical immunotherapy in superﬁcial bladder cancer patients and
the fact that its production was developed approximately 20 years
ago, development of new techniques that could support potential mod-
ernization of the manufacturing process of BCG IT would have great
clinical importance.
Executive summary
Background
• An electrical sensing zone (ESZ) method development, optimization,
and qualiﬁcation are described, with speciﬁc focus on Immucyst®, a
BCG IT product characterization.
Method development study design
• Aspects to consider in development study: purpose and scope of the
analytical procedure, product type, experimental design, and data
analysis including the use of statistical methods.
• Aspects of ESZ method development and optimization are discussed,
including rationale, reporting values, desirable performance, and
characteristics (in this case, precision and lot-to-lot consistency).
Results and discussion
• ESZmethod development is presented to characterize visible and sub-
visible population of particulates present in BCG IT lyophilized
reconstituted product.
Conclusions & recommendations
• Successful completion of the development study provides scientiﬁc
evidence that the method is suitable for characterization of BCG IT
reconstituted lyophilized product. Further qualiﬁcation can also pro-
vide guidance and useful information for the eventual method valida-
tion, where required.
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